false2024Q10000055529--04-3000000555292023-05-012023-07-3100000555292023-08-29xbrli:sharesiso4217:USD00000555292022-05-012022-07-31iso4217:USDxbrli:shares0000055529us-gaap:CommonStockMember2023-04-300000055529us-gaap:AdditionalPaidInCapitalMember2023-04-300000055529us-gaap:TreasuryStockCommonMember2023-04-300000055529us-gaap:RetainedEarningsMember2023-04-300000055529us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-3000000555292023-04-300000055529us-gaap:RetainedEarningsMember2023-05-012023-07-310000055529us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-05-012023-07-310000055529us-gaap:CommonStockMember2023-05-012023-07-310000055529us-gaap:AdditionalPaidInCapitalMember2023-05-012023-07-310000055529us-gaap:CommonStockMember2023-07-310000055529us-gaap:AdditionalPaidInCapitalMember2023-07-310000055529us-gaap:TreasuryStockCommonMember2023-07-310000055529us-gaap:RetainedEarningsMember2023-07-310000055529us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-3100000555292023-07-310000055529us-gaap:CommonStockMember2022-04-300000055529us-gaap:AdditionalPaidInCapitalMember2022-04-300000055529us-gaap:TreasuryStockCommonMember2022-04-300000055529us-gaap:RetainedEarningsMember2022-04-300000055529us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-3000000555292022-04-300000055529us-gaap:RetainedEarningsMember2022-05-012022-07-310000055529us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-05-012022-07-310000055529us-gaap:CommonStockMember2022-05-012022-07-310000055529us-gaap:AdditionalPaidInCapitalMember2022-05-012022-07-310000055529us-gaap:CommonStockMember2022-07-310000055529us-gaap:AdditionalPaidInCapitalMember2022-07-310000055529us-gaap:TreasuryStockCommonMember2022-07-310000055529us-gaap:RetainedEarningsMember2022-07-310000055529us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-3100000555292022-07-310000055529us-gaap:TransferredOverTimeMemberus-gaap:GeographicDistributionDomesticMember2023-05-012023-07-310000055529us-gaap:GeographicDistributionForeignMemberus-gaap:TransferredOverTimeMember2023-05-012023-07-310000055529us-gaap:TransferredOverTimeMember2023-05-012023-07-310000055529us-gaap:TransferredOverTimeMemberus-gaap:GeographicDistributionDomesticMember2022-05-012022-07-310000055529us-gaap:GeographicDistributionForeignMemberus-gaap:TransferredOverTimeMember2022-05-012022-07-310000055529us-gaap:TransferredOverTimeMember2022-05-012022-07-310000055529us-gaap:TransferredAtPointInTimeMemberus-gaap:GeographicDistributionDomesticMember2023-05-012023-07-310000055529us-gaap:GeographicDistributionForeignMemberus-gaap:TransferredAtPointInTimeMember2023-05-012023-07-310000055529us-gaap:TransferredAtPointInTimeMember2023-05-012023-07-310000055529us-gaap:TransferredAtPointInTimeMemberus-gaap:GeographicDistributionDomesticMember2022-05-012022-07-310000055529us-gaap:GeographicDistributionForeignMemberus-gaap:TransferredAtPointInTimeMember2022-05-012022-07-310000055529us-gaap:TransferredAtPointInTimeMember2022-05-012022-07-310000055529us-gaap:GeographicDistributionDomesticMember2023-05-012023-07-310000055529us-gaap:GeographicDistributionForeignMember2023-05-012023-07-310000055529us-gaap:GeographicDistributionDomesticMember2022-05-012022-07-310000055529us-gaap:GeographicDistributionForeignMember2022-05-012022-07-310000055529us-gaap:AccountsReceivableMember2023-07-310000055529us-gaap:OtherNoncurrentAssetsMember2023-07-310000055529us-gaap:AccountsReceivableMember2023-04-300000055529us-gaap:OtherNoncurrentAssetsMember2023-04-3000000555292022-05-012023-04-30xbrli:pure0000055529kequ:ForeignSubsidiariesMember2023-07-310000055529kequ:ForeignSubsidiariesMember2023-04-300000055529kequ:TradingSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-07-310000055529kequ:TradingSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-07-310000055529kequ:TradingSecuritiesMember2023-07-310000055529us-gaap:FairValueInputsLevel1Memberus-gaap:CashSurrenderValueMember2023-07-310000055529us-gaap:FairValueInputsLevel2Memberus-gaap:CashSurrenderValueMember2023-07-310000055529us-gaap:CashSurrenderValueMember2023-07-310000055529us-gaap:FairValueInputsLevel1Member2023-07-310000055529us-gaap:FairValueInputsLevel2Member2023-07-310000055529us-gaap:FairValueInputsLevel1Memberkequ:NonQualifiedCompensationPlanMember2023-07-310000055529us-gaap:FairValueInputsLevel2Memberkequ:NonQualifiedCompensationPlanMember2023-07-310000055529kequ:NonQualifiedCompensationPlanMember2023-07-310000055529kequ:TradingSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-04-300000055529kequ:TradingSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-04-300000055529kequ:TradingSecuritiesMember2023-04-300000055529us-gaap:FairValueInputsLevel1Memberus-gaap:CashSurrenderValueMember2023-04-300000055529us-gaap:FairValueInputsLevel2Memberus-gaap:CashSurrenderValueMember2023-04-300000055529us-gaap:CashSurrenderValueMember2023-04-300000055529us-gaap:FairValueInputsLevel1Member2023-04-300000055529us-gaap:FairValueInputsLevel2Member2023-04-300000055529us-gaap:FairValueInputsLevel1Memberkequ:NonQualifiedCompensationPlanMember2023-04-300000055529us-gaap:FairValueInputsLevel2Memberkequ:NonQualifiedCompensationPlanMember2023-04-300000055529kequ:NonQualifiedCompensationPlanMember2023-04-30kequ:CompensationPlan0000055529us-gaap:LineOfCreditMemberkequ:CreditAgreementMidCapFundingIVTrustMemberus-gaap:RevolvingCreditFacilityMember2023-04-300000055529kequ:InternationalSubsidiariesMember2023-04-300000055529us-gaap:LineOfCreditMemberkequ:CreditAgreementMidCapFundingIVTrustMemberus-gaap:RevolvingCreditFacilityMember2023-07-310000055529kequ:InternationalSubsidiariesMember2023-07-31kequ:renewalOption0000055529us-gaap:BuildingMember2023-05-012023-07-310000055529us-gaap:LandMember2023-07-310000055529us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberkequ:TwoThousandSeventeenOmnibusIncentivePlanMember2023-06-012023-06-300000055529us-gaap:RestrictedStockUnitsRSUMemberkequ:TwoThousandSeventeenOmnibusIncentivePlanMember2023-05-012023-07-310000055529us-gaap:RestrictedStockUnitsRSUMemberkequ:TwoThousandSeventeenOmnibusIncentivePlanMember2023-07-310000055529us-gaap:RestrictedStockUnitsRSUMemberkequ:TwoThousandSeventeenOmnibusIncentivePlanMember2022-05-012022-07-31kequ:Segment0000055529us-gaap:OperatingSegmentsMemberkequ:DomesticOperationsMember2023-05-012023-07-310000055529us-gaap:OperatingSegmentsMemberkequ:InternationalOperationsMember2023-05-012023-07-310000055529kequ:CorporateAndEliminationsMember2023-05-012023-07-310000055529us-gaap:OperatingSegmentsMemberkequ:DomesticOperationsMember2022-05-012022-07-310000055529us-gaap:OperatingSegmentsMemberkequ:InternationalOperationsMember2022-05-012022-07-310000055529kequ:CorporateAndEliminationsMember2022-05-012022-07-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________
FORM 10-Q
_________________________
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 31, 2023
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission file number 0-5286
_________________________
KEWAUNEE SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
_________________________
Delaware 38-0715562
(State or other jurisdiction of
incorporation or organization)		 (IRS Employer
Identification No.)
2700 West Front Street
Statesville, North Carolina
 28677-2927
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (704) 873-7202
Securities registered pursuant to Section 12(b) of the Act:

    Title of Each Class            Trading Symbol(s)    Name of Exchange on which registered
Common Stock, $2.50 par value             KEQU             NASDAQ Global Market
            
_________________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐  Accelerated filer 
☐
Non-accelerated filer 
☒
  Smaller reporting company 
☒
   Emerging growth company 
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
As of August 29, 2023, the registrant had outstanding 2,904,094 shares of Common Stock.



KEWAUNEE SCIENTIFIC CORPORATION
INDEX TO FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED JULY 31, 2023
  Page Number

i

Part 1. Financial Information
Item 1.    Condensed Consolidated Financial Statements

Kewaunee Scientific Corporation
Condensed Consolidated Statements of Operations
(Unaudited)
($ and shares in thousands, except per share amounts)
 Three Months Ended
July 31,
 20232022
Net sales$49,839 $50,123 
Cost of products sold37,925 43,927 
Gross profit11,914 6,196 
Operating expenses8,106 6,592 
Operating profit (loss)3,808 (396)
Pension expense(41)(27)
Other income, net75 467 
Interest expense(430)(384)
Profit (loss) before income taxes3,412 (340)
Income tax expense897 379 
Net earnings (loss)2,515 (719)
Less: Net earnings attributable to the non-controlling interest41 28 
Net earnings (loss) attributable to Kewaunee Scientific Corporation$2,474 $(747)
Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders
Basic$0.87 $(0.27)
Diluted$0.86 $(0.27)
Weighted average number of common shares outstanding
Basic2,860 2,807 
Diluted2,885 2,807 









See accompanying notes to Condensed Consolidated Financial Statements.
1

Kewaunee Scientific Corporation
Condensed Consolidated Statements of Comprehensive Earnings (Loss)
(Unaudited)
($ in thousands)
 Three Months Ended
July 31,
 20232022
Net earnings (loss)$2,515 $(719)
Other comprehensive loss, net of tax:
Foreign currency translation adjustments(144)(224)
Other comprehensive loss(144)(224)
Comprehensive earnings (loss), net of tax2,371 (943)
Less: Comprehensive income attributable to the non-controlling interest41 28 
Comprehensive earnings (loss) attributable to Kewaunee Scientific Corporation$2,330 $(971)





















See accompanying notes to Condensed Consolidated Financial Statements.
2

Kewaunee Scientific Corporation
Condensed Consolidated Statements of Stockholders' Equity
(Unaudited)
($ in thousands, except per share amounts)
 Common
Stock		Additional
Paid-in
Capital		Treasury
Stock		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		Total Kewaunee Scientific Corporation Stockholders' Equity
Balance at April 30, 2023$7,084 $5,059 $(53)$28,761 $(3,442)$37,409 
Net earnings attributable to Kewaunee Scientific Corporation— — — 2,474 — 2,474 
Other comprehensive loss— — — — (144)(144)
Stock-based compensation185 (494)— — — (309)
Balance at July 31, 2023$7,269 $4,565 $(53)$31,235 $(3,586)$39,430 

 Common
Stock		Additional
Paid-in
Capital		Treasury
Stock		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		Total Kewaunee Scientific Corporation Stockholders' Equity
Balance at April 30, 2022$6,983 $4,483 $(53)$28,023 $(3,742)$35,694 
Net loss attributable to Kewaunee Scientific Corporation— — — (747)— (747)
Other comprehensive loss— — — — (224)(224)
Stock-based compensation97 (134)— — — (37)
Balance at July 31, 2022$7,080 $4,349 $(53)$27,276 $(3,966)$34,686 















See accompanying notes to Condensed Consolidated Financial Statements.
3

Kewaunee Scientific Corporation
Condensed Consolidated Balance Sheets
($ and shares in thousands, except per share amounts)
July 31, 2023April 30, 2023
 (Unaudited) 
Assets
Current Assets:
Cash and cash equivalents$12,699 $8,078 
Restricted cash8,869 5,737 
Receivables, less allowance; $560; $476, on each respective date
42,461 46,081 
Inventories22,126 21,889 
Prepaid expenses and other current assets7,365 6,135 
Total Current Assets93,520 87,920 
Property, plant and equipment, at cost63,023 61,368 
Accumulated depreciation(45,684)(44,966)
Net Property, Plant and Equipment17,339 16,402 
Right of use assets8,612 9,170 
Other assets5,347 5,406 
Total Assets$124,818 $118,898 
Liabilities and Stockholders' Equity
Current Liabilities:
Short-term borrowings$5,054 $3,587 
Current portion of financing liability659 642 
Current portion of financing lease liabilities86 85 
Current portion of operating lease liabilities1,912 1,967 
Accounts payable22,140 23,599 
Employee compensation and amounts withheld4,903 4,304 
Deferred revenue7,067 4,097 
Other accrued expenses2,408 1,772 
Total Current Liabilities44,229 40,053 
Long-term portion of financing liability27,958 28,132 
Long-term portion of financing lease liabilities143 148 
Long-term portion of operating lease liabilities6,645 7,136 
Accrued pension and deferred compensation costs3,861 3,546 
Deferred income taxes989 943 
Other non-current liabilities453 455 
Total Liabilities84,278 80,413 
Commitments and Contingencies
Stockholders' Equity:
Common stock, $2.50 par value, Authorized – 5,000 shares; Issued – 2,907 shares; 2,833 shares; – Outstanding – 2,904 shares; 2,830 shares, on each respective date
7,269 7,084 
Additional paid-in-capital4,565 5,059 
Retained earnings31,235 28,761 
Accumulated other comprehensive loss(3,586)(3,442)
Common stock in treasury, at cost, 3 shares, on each respective date
(53)(53)
Total Kewaunee Scientific Corporation Stockholders' Equity39,430 37,409 
Non-controlling interest1,110 1,076 
Total Stockholders' Equity40,540 38,485 
Total Liabilities and Stockholders' Equity$124,818 $118,898 

See accompanying notes to Condensed Consolidated Financial Statements.
4

Kewaunee Scientific Corporation
Condensed Consolidated Statements of Cash Flows
(Unaudited)
($ in thousands)
 Three Months Ended
July 31,
 20232022
Cash flows from operating activities:
Net earnings (loss)$2,515 $(719)
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:
Depreciation718 725 
Bad debt provision125 23 
Stock-based compensation expense183 172 
Deferred income taxes46 23 
Change in assets and liabilities:
Receivables3,496 516 
Inventories(237)(1,304)
Accounts payable and other accrued expenses(226)(2,117)
Deferred revenue2,970 10,587 
Other, net(1,418)(4,221)
Net cash provided by operating activities8,172 3,685 
Cash flows from investing activities:
Capital expenditures(1,654)(390)
Net cash used in investing activities(1,654)(390)
Cash flows from financing activities:
Proceeds from short-term borrowings40,597 4,431 
Repayments on short-term borrowings(39,130)(6,019)
Proceeds from sale-leaseback financing transaction— 13,456 
Payments on sale-leaseback financing transaction(157)(140)
Payments on long-term lease obligations(4)(58)
Net cash provided by financing activities1,306 11,670 
Effect of exchange rate changes on cash, cash equivalents and restricted cash(71)(325)
Increase in cash, cash equivalents and restricted cash7,753 14,640 
Cash, cash equivalents and restricted cash, beginning of period13,815 6,894 
Cash, cash equivalents and restricted cash, end of period$21,568 $21,534 










See accompanying notes to Condensed Consolidated Financial Statements.
5

Kewaunee Scientific Corporation
Notes to Condensed Consolidated Financial Statements
(unaudited)
A. Financial Information
The unaudited interim Condensed Consolidated Financial Statements of Kewaunee Scientific Corporation (the "Company") have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.
These interim Condensed Consolidated Financial Statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the Consolidated Financial Statements and Notes included in the Company's 2023 Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The Condensed Consolidated Balance Sheet as of April 30, 2023 included in this interim period filing has been derived from the audited consolidated financial statements at that date, but does not include all of the information and related notes required by GAAP for complete financial statements.
The preparation of the interim Condensed Consolidated Financial Statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

B. Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents consist of cash on hand and highly liquid investments with original maturities of three months or less. During the three months ended July 31, 2023 and twelve months ended April 30, 2023, the Company had cash deposits in excess of FDIC insured limits. The Company has not experienced any losses from such deposits. Restricted cash includes bank deposits of subsidiaries used for performance guarantees against customer orders and domestic bank deposits used as collateral for an outstanding letter of credit.
The Company includes restricted cash along with the cash balance for presentation in the Condensed Consolidated Statements of Cash Flows. The reconciliation between the Condensed Consolidated Balance Sheet and the Condensed Consolidated Statement of Cash Flows is as follows:
July 31, 2023April 30, 2023
Cash and cash equivalents$12,699 $8,078 
Restricted cash8,869 5,737 
Total cash, cash equivalents and restricted cash$21,568 $13,815 

C. Revenue Recognition
The Company recognizes revenue when control of a good or service promised in a contract (i.e., performance obligation) is transferred to a customer. Control is obtained when a customer has the ability to direct the use of and obtain substantially all of the remaining benefits from that good or service. The majority of the Company's revenues are recognized over time as the customer receives control as the Company performs work under a contract. However, a portion of the Company's revenues are recognized at a point-in-time as control is transferred at a distinct point in time per the terms of a contract.
6

Disaggregated Revenue
A summary of net sales transferred to customers over time and at a point in time for the periods ended July 31, 2023 and July 31, 2022 is as follows (in thousands):
Three Months Ended
 July 31, 2023July 31, 2022
 DomesticInternationalTotalDomesticInternationalTotal
Over Time$33,904 $14,419 $48,323 $35,353 $12,655 $48,008 
Point in Time1,516 — 1,516 2,115 — 2,115 
Total$35,420 $14,419 $49,839 $37,468 $12,655 $50,123 

Contract Balances
The closing balances of contract assets included $13,621,000 in accounts receivable and $928,000 in other assets at July 31, 2023. The opening balance of contract assets arising from contracts with customers included $13,459,000 in accounts receivable and $1,191,000 in other assets at April 30, 2023. The closing and opening balances of contract liabilities included in deferred revenue arising from contracts with customers were $7,067,000 at July 31, 2023 and $4,097,000 at April 30, 2023. The timing of revenue recognition, billings and cash collections results in accounts receivable, unbilled receivables, and deferred revenue which are disclosed in the Condensed Consolidated Balance Sheets and in the Notes to the Condensed Consolidated Financial Statements. In general, the Company receives payments from customers based on a billing schedule established in its contracts. Unbilled receivables represent amounts earned which have not yet been billed in accordance with contractually stated billing terms and are included in receivables on the Condensed Consolidated Balance Sheets. Receivables are recorded when the right to consideration becomes unconditional and the Company has a right to invoice the customer. Deferred revenue relates to payments received in advance of performance under the contract. Deferred revenue is recognized as revenue as (or when) the Company performs under the contract. Approximately 100% of the contract liability balances at April 30, 2023 and July 31, 2023 are expected to be recognized as revenue during the respective succeeding 12 months.
D. Inventories
The Company measures inventory using the first-in, first-out method at the lower of cost or net realizable value. Inventories consisted of the following (in thousands):
July 31, 2023April 30, 2023
Finished products$3,537 $3,412 
Work in process2,138 2,380 
Raw materials16,451 16,097 
Total$22,126 $21,889 
The Company's International subsidiaries' inventories were $2,902,000 at July 31, 2023 and $2,740,000 at April 30, 2023 and are included in the above tables.
7

E. Fair Value of Financial Instruments
The Company's financial instruments consist primarily of cash and equivalents, mutual funds, short-term borrowings, and the cash surrender value of life insurance policies. The carrying value of these assets and liabilities approximates their fair value. The following tables summarize the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of July 31, 2023 and April 30, 2023 (in thousands):
 July 31, 2023
Financial AssetsLevel 1Level 2Total
Trading securities held in non-qualified compensation plans (1)
$1,324 $— $1,324 
Cash surrender value of life insurance policies (1)
— 1,401 1,401 
Total$1,324 $1,401 $2,725 
Financial Liabilities
Non-qualified compensation plans (2)
$— $3,185 $3,185 
Total$— $3,185 $3,185 
 April 30, 2023
Financial AssetsLevel 1Level 2Total
Trading securities held in non-qualified compensation plans (1)
$1,105 $— $1,105 
Cash surrender value of life insurance policies (1)
— 1,358 1,358 
Total$1,105 $1,358 $2,463 
Financial Liabilities
Non-qualified compensation plans (2)
$— $2,910 $2,910 
Total$— $2,910 $2,910 
(1)The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value.
(2)Plan liabilities are equal to the individual participants' account balances and other earned retirement benefits.

F. Long-term Debt and Other Credit Arrangements
At April 30, 2023, advances of $3.5 million were outstanding under the Company's Revolving Credit Facility. Amounts available under the Revolving Credit Facility were $10.3 million at April 30, 2023. The borrowing rate under the Revolving Credit Facility was 9.02% as of April 30, 2023. The Company's International subsidiaries had a balance outstanding of $39,000 in short-term borrowings related to overdraft protection and short-term loan arrangements. At April 30, 2023, the Company was in compliance with all of the financial covenants under its Revolving Credit Facility.
At July 31, 2023, there were $5.0 million outstanding under the Revolving Credit Facility, with remaining borrowing capacity under the Revolving Credit Facility of $8.3 million. The borrowing rate under the Revolving Credit Facility was 9.33% as of July 31, 2023. In addition, the Company's International subsidiaries have a balance outstanding of $54,000 in short-term borrowings related to overdraft protection and short-term loan arrangements. As of July 31, 2023, the Company was in compliance with all of the financial covenants under its Revolving Credit Facility.

G. Sale-Leaseback Financing Transaction

On December 22, 2021, the Company entered into an Agreement for Purchase and Sale of Real Property with CAI Investments Sub-Series 100 LLC, a Nevada limited liability company (the "Buyer"), for the Company’s headquarters and manufacturing facilities located at 2700 West Front Street in Statesville, North Carolina (the "Sale Agreement").
The Sale Agreement was finalized on March 24, 2022 and coincided with the Company and CAI Investments Medical Products I Master Lessee LLC ("Lessor") entering into a lease agreement. The lease arrangement is for a 20-year term, with four renewal options of five years each. Under the terms of the lease agreement, the Company’s initial basic rent is approximately $158,000 per month, with annual increases of approximately 2% each year of the initial term.
The Company accounted for the Sale-Leaseback Arrangement as a financing transaction as the lease agreement was determined to be a finance lease due to the significance of the present value of the lease payments, using a discount rate of 4.75% to reflect
8

the Company’s incremental borrowing rate, compared to the fair value of the leased property as of the lease commencement date. In measuring the lease payments for the present value analysis, the Company elected the practical expedient to combine the lease component (the leased facilities) with the non-lease component (property management provided by the Buyer/Lessor) into a single lease component.
The presence of a finance lease indicates that control of the property has not transferred to the Buyer/Lessor and, as such, the transaction was deemed a failed sale-leaseback and accounted for as a financing arrangement. As a result of this determination, the Company is viewed as having received the sale proceeds from the Buyer/Lessor in the form of a hypothetical loan collateralized by its leased facilities. The hypothetical loan is payable as principal and interest in the form of “lease payments” to the Buyer/Lessor. As such, the Company will not derecognize the property from its books for accounting purposes until the lease ends. No gain or loss was recognized under GAAP related to the Sale-Leaseback Arrangement.
As of July 31, 2023, the carrying value of the financing liability was $28,617,000, net of $692,000 in debt issuance costs, of which $659,000 was classified as current on the Consolidated Balance Sheet with $27,958,000 classified as long-term. As of April 30, 2023, the carrying value of the financing liability was $28,774,000, net of $708,000 in debt issuance costs, of which $642,000 was classified as current on the Consolidated Balance Sheet with $28,132,000 classified as long-term. The monthly lease payments are split between a reduction of principal and interest expense using the effective interest rate method. Interest expense associated with the financing arrangement was $325,000 and $332,000 for the three months ended July 31, 2023 and July 31, 2022, respectively.
The Company will depreciate the building down to zero over the 20-year assumed economic life of the Property so that at the end of the lease term, the remaining carrying amount of the financing liability will equal the carrying amount of the land of $41,000.
Remaining future cash payments related to the financing liability as of July 31, 2023 are as follows:
($ in thousands)
Remainder of 2024$1,449 
20251,970 
20262,009 
20272,050 
20282,090 
Thereafter33,867 
Total Minimum Liability Payments43,435 
Imputed Interest(14,818)
Total$28,617 

H. Leases
The Company recognizes lease assets and lease liabilities reflecting the rights and obligations created by operating type leases for real estate and equipment in both the U.S. and internationally and financing leases for a truck and IT equipment in the U.S. At July 31, 2023 and April 30, 2023, right-of-use assets totaled $8,612,000 and $9,170,000, respectively. Operating cash paid to settle lease liabilities was $639,000 and $524,000 for the three months ended July 31, 2023 and July 31, 2022, respectively. The Company's leases have remaining lease terms of up to 9 years. In addition, some of the leases may include options to extend the leases for up to 5 years or options to terminate the leases within 1 year. Operating lease expenses were $867,000 for the three months ended July 31, 2023, inclusive of period cost for short-term leases, not included in lease liabilities, of $228,000. Operating lease expenses were $835,000 for the three months ended July 31, 2022, inclusive of period cost for short-term leases, not included in lease liabilities, of $311,000.
At July 31, 2023, the weighted average remaining lease term for the capitalized operating leases was 4.9 years and the weighted average discount rate was 5.0%. For the financing leases, the weighted average remaining lease term was 2.9 years and the weighted average discount rate was 6.7%. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of those lease payments. The Company uses the implicit rate when readily determinable.
9

Future minimum lease payments under non-cancelable leases as of July 31, 2023 were as follows:
OperatingFinancing
Remainder of fiscal 2024$1,730 $83 
20252,172 91 
20261,917 71 
20271,654 — 
20281,127 — 
Thereafter1,377 — 
Total Minimum Lease Payments9,977 245 
Imputed Interest(1,421)(16)
Total$8,556 $229 
I. Earnings Per Share
Basic earnings per share is based on the weighted average number of common shares outstanding during the year. Diluted earnings per share reflects the assumed exercise of outstanding options and the conversion of restricted stock units ("RSUs") under the Company's various stock compensation plans, except when RSUs and options have an antidilutive effect. There were 33,700 and 104,141 antidilutive RSUs and options outstanding at July 31, 2023 and July 31, 2022, respectively. The following is a reconciliation of basic to diluted weighted average common shares outstanding (in thousands):
Three Months Ended
July 31, 2023July 31, 2022
Basic2,860 2,807 
Dilutive effect of stock options and RSUs25 — 
Weighted average common shares outstanding - diluted2,885 2,807 
J. Stock Options and Stock-based Compensation
The Company recognizes compensation costs related to stock options and other stock awards granted by the Company as operating expenses over their vesting period.
In June 2023, the Company granted 87,220 RSUs under the 2017 Omnibus Incentive Plan ("2017 Plan"). These RSUs include both a service and a performance component, vesting over a three-year period. The recognized expense is based upon the vesting period for service criteria and estimated attainment of the performance criteria at the end of the three-year period, based on the ratio of cumulative days of service to total days over the three-year period. The Company recorded stock-based compensation expense during the three months ended July 31, 2023 of $173,000 with the remaining estimated stock-based compensation expense of $2,032,000 to be recorded over the remaining vesting periods. The Company recorded stock-based compensation expense during the three months ended July 31, 2022 of $131,000. Directors' fees paid with shares of common stock in lieu of cash in accordance with Director compensation guidelines were $10,000 and $41,000 for the three month periods ended July 31, 2023 and July 31, 2022, respectively, and were also included in the stock-based compensation on the Condensed Consolidated Statements of Cash Flows.
K. Income Taxes
Income tax expense of $897,000 and $379,000 was recorded for the three months ended July 31, 2023 and July 31, 2022, respectively. The effective tax rate was 26.3% and (111.5)% for the three months ended July 31, 2023 and July 31, 2022, respectively. The effective tax rate for the three months ended July 31, 2023 reflects the impact of foreign operations which are taxed at different rates than the U.S. tax rate of 21%, combined with expected current year tax expense for the Company's domestic operations in excess of the change in domestic valuation allowance required for the fiscal year. The effective tax rate for the three months ended July 31, 2022 reflected the impact of foreign operations and the recording of a valuation allowance against the deferred tax asset which resulted in the elimination of any U.S. income tax benefit for pretax losses incurred during the period.
In August 2019, the Company revoked its indefinite reinvestment of foreign unremitted earnings position in compliance with ASC 740 "Income Taxes" and terminated its indefinite reinvestment of unremitted earnings assertion for the Singapore and
10

Kewaunee Labway India Pvt. Ltd. international subsidiaries. The Company has a deferred tax liability of $1,363,000 and $1,318,000 for the withholding tax related to Kewaunee Labway India Pvt. Ltd. as of July 31, 2023 and April 30, 2023, respectively.
L. Defined Benefit Pension Plans
The Company has non-contributory defined benefit pension plans covering substantially all domestic salaried and hourly employees. These plans were amended as of April 30, 2005; no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. There were no Company contributions paid to the plans for the three months ended July 31, 2023 and July 31, 2022. The Company assumed an expected long-term rate of return of 7.75% for the periods ended July 31, 2023 and July 31, 2022.
Pension expense consisted of the following (in thousands):
Three Months Ended
July 31, 2023July 31, 2022
Service cost$— $— 
Interest cost224 322 
Expected return on plan assets(328)(535)
Recognition of net loss145 240 
Net periodic pension expense$41 $27 
M. Segment Information
The Company's operations are classified into two business segments: Domestic and International. The Domestic business segment principally designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, worksurfaces, workstations, workbenches, and computer enclosures. The International business segment, which consists of the Company's foreign subsidiaries, provides products and services, including facility design, detailed engineering, construction, and project management from the planning stage through testing and commissioning of laboratories. Intersegment transactions are recorded at normal profit margins. All intercompany balances and transactions have been eliminated. Certain corporate expenses shown below have not been allocated to the business segments.
The following tables provide financial information by business segment and unallocated corporate expenses for the periods ended July 31, 2023 and 2022 (in thousands):
Domestic
Operations		International
Operations		Corporate /
Eliminations		Total
Three months ended July 31, 2023
Revenues from external customers$35,420 $14,419 $— $49,839 
Intersegment revenues51 661 (712)— 
Earnings (loss) before income taxes3,623 793 (1,004)3,412 
Three months ended July 31, 2022
Revenues from external customers$37,468 $12,655 $— $50,123 
Intersegment revenues796 1,621 (2,417)— 
Earnings (loss) before income taxes98 1,094 (1,532)(340)
N. New Accounting Standards
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments," which replaces the current incurred loss method used for determining credit losses on financial assets, including trade receivables, with an expected credit loss method. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company adopted this standard in fiscal year 2024. The adoption of this standard did not have a significant impact on the Company's consolidated financial position or results of operations.
11

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations
The Company's 2023 Annual Report to Stockholders on Form 10-K contains management's discussion and analysis of the Company's financial condition and results of operations as of and for the fiscal year ended April 30, 2023. The following discussion and analysis describes material changes in the Company's financial condition since April 30, 2023. The analysis of results of operations compares the three months ended July 31, 2023 with the comparable periods of the prior year.
Results of Operations
Sales for the quarter were $49,839,000, an decrease from sales of $50,123,000 in the comparable period of the prior year. Domestic sales for the quarter were $35,420,000, down 5.5% from sales of $37,468,000 in the comparable period of the prior year. The decrease in Domestic sales was predominantly related to the reduction of installation revenue related to the Company's decision to no longer sell directly to end users, which typically included installation services. International sales for the quarter were $14,419,000, up 13.9% from sales of $12,655,000 in the comparable period of the prior year. International sales increased when compared to the prior year period due to the delivery of several large projects that were booked in the prior fiscal year.
The Company's order backlog was $140.8 million at July 31, 2023, as compared to $174.0 million at July 31, 2022, and $147.9 million at April 30, 2023.
The gross profit margin for the three months ended July 31, 2023 was 23.9% of sales, as compared to 12.4% of sales in the comparable quarter of the prior year. The increase in gross profit margin percentage for the three months ended July 31, 2023 is primarily being generated from Domestic operations. The increase is driven by the pricing of new orders in response to higher raw material input costs when compared to the prior year period, during which 25% of Domestic revenue related to direct orders that, in aggregate, were delivered at a loss for the Company.
Operating expenses for the three months ended July 31, 2023 were $8,106,000, or 16.3% of sales, as compared to $6,592,000, or 13.2% of sales, in the comparable period of the prior year. The increase in operating expenses for the three months ended July 31, 2023 was primarily due to increases in SG&A wages, benefits, incentive and stock-based compensation of $823,000, bad debt expense primarily related to a single job dispute of $102,000, travel and entertainment expenses of $102,000, and increases in international operating expenses of $170,000.
Interest expense, net was $430,000 for the three months ended July 31, 2023, as compared to $384,000 for the comparable period of the prior year. The changes in interest expense were due to changes in the levels of bank borrowings and interest rates.
The effective income tax rate for the three months ended July 31, 2023 was 26.3%, as compared to (111.5)% for the three months ended July 31, 2022. Income tax expense of $897,000 and $379,000 was recorded for the three months ended July 31, 2023 and 2022, respectively. The effective tax rate for the three months ended July 31, 2023 reflects the impact of foreign operations which are taxed at different rates than the U.S. tax rate of 21%, combined with expected current year tax expense for the Company's domestic operations in excess of the change in domestic valuation allowance required for the fiscal year. The effective rate for the three months ended July 31, 2022 reflected the impact of the domestic valuation allowance against the deferred tax asset, which resulted in the elimination of any U.S. income tax benefit for the losses incurred during the period. See Note K, Income Taxes, of the Notes to Condensed Consolidated Financial Statements for additional information.
Non-controlling interests related to the Company's subsidiaries not 100% owned by the Company decreased net earnings by $41,000 for the three months ended July 31, 2023, compared to $28,000, for the comparable period of the prior year. The change in the net earnings attributable to the non-controlling interest in the current period was due to changes in earnings of the subsidiaries in the related period.
Net earnings was $2,474,000, or $0.86 per diluted share, for the three months ended July 31, 2023, compared to a net loss of $747,000, or $(0.27) per diluted share, in the prior year period.
Liquidity and Capital Resources
Our principal sources of liquidity have historically been funds generated from operating activities, supplemented as needed by borrowings under our Revolving Credit Facility. Additionally, certain machinery and equipment are financed by non-cancellable operating and financing leases. The Company believes that these sources will be sufficient to support ongoing business requirements in the current fiscal year, including capital expenditures.
The Company had working capital of $49,291,000 at July 31, 2023, compared to $47,867,000 at April 30, 2023. The ratio of current assets to current liabilities was 2.1-to-1.0 at July 31, 2023, compared to 2.2-to-1.0 at April 30, 2023.
12

The Company provided cash of $8,172,000 during the three months ended July 31, 2023, primarily from operations and decreases in accounts receivable of $3.5 million and increases in deferred revenue of $3.0 million, partially offset by increases in other current assets of $999,000 and accrued employee compensation and amounts withheld of $315,000. During the three months ended July 31, 2023, the Company used net cash of $1,654,000 in investing activities, all of which was used for capital expenditures. The Company's financing activities provided cash of $1,306,000 during the three months ended July 31, 2023, primarily from a net increase in borrowings under the Revolving Credit Facility.
Outlook
The Company's ability to predict future demand for its products continues to be limited given its role as subcontractor or supplier to dealers for subcontractors. Demand for the Company's products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Company's earnings are also impacted by fluctuations in prevailing pricing for projects in the laboratory construction marketplace and costs of raw materials, including steel, wood, and epoxy resin.
The Company is operating more efficiently than in the past due to its ability to focus solely on supporting its dealers and distribution channel partners domestically while continuing to provide turnkey solutions in the international markets it serves. The improved focus of the organization, combined with a strong global management team, a healthy backlog, improved manufacturing capabilities, and end-use markets that continue to prioritize investment in projects that require the products Kewaunee designs and manufactures positions the Company well.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain statements in this document constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements other than statements of historical fact included in this Annual Report, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers’ required delivery schedules; risks related to fluctuations in the Company’s operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such differences are described under the caption "Risk Factors" in Item 1A in the Company's 2023 Annual Report on Form 10-K, which you should review carefully. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
There are no material changes to the disclosures made on this matter in the Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2023.
Item 4.    Controls and Procedures
(a) Evaluation of disclosure controls and procedures
An evaluation was performed under the supervision and with the participation of the Company's management, including the Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of July 31, 2023. Based on that evaluation, the Company's management, including the CEO and CFO, concluded that, as of July 31, 2023, the Company's disclosure controls and procedures were adequate and effective and
13

designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.
(b) Changes in internal controls
There was no significant change in the Company's internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.
14

PART II. OTHER INFORMATION
Item 1A.    Risk Factors
The business, financial condition and operating results of the Company can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in Part I, Item 1A of the Company's 2023 Annual Report on Form 10-K under the heading "Risk Factors," any one or more of which could, directly or indirectly, cause the Company's actual financial condition and operating results to vary materially from its past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect the Company's business, financial condition, operating results and stock price. There have been no material changes to the Company's risk factors from those set forth in the Company's Annual Report on Form 10-K for the year ended April 30, 2023 as filed with the SEC on June 30, 2023.
Item 5. Other Information
On August 31, 2023, the Board of Directors of Kewaunee Scientific Corporation (the "Company") adopted a new share repurchase program to take effect starting September 1, 2023. The Board of Directors authorized the repurchase of up to 100,000 shares of the Company's common stock under the new program, which does not have a specified expiration date.
The timing and amount of any repurchases under this program will be determined by the Company's management at its discretion based upon its ongoing assessments of the capital needs of the business, the market price of the Company's common stock and general market conditions. Share repurchases under this program may be made through a variety of methods including open-market purchases, block trades, exchange transactions or any combination thereof. The program does not obligate the Company to acquire any particular amount of its common stock, and the share repurchase program may be suspended or discontinued at any time at the Company's discretion.
Item 6.    Exhibits
10.1(1)
31.1
31.2
32.1
32.2
101.INSXBRL Instance Document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

(1) Filed as an exhibit to the Kewaunee Scientific Corporation Current Report on Form 8-K (Commission File No. 0-5286) filed with the Securities and Exchange Commission on August 25, 2023, and incorporated herein by reference.
15

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 KEWAUNEE SCIENTIFIC CORPORATION
                             (Registrant)
Date: September 1, 2023 By/s/ Donald T. Gardner III
 Donald T. Gardner III
 (As duly authorized officer and Vice President, Finance and Chief Financial Officer)

16
Exhibit 31.1 CERTIFICATION I, Thomas D. Hull III, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Kewaunee Scientific Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. /s/ Thomas D. Hull III Thomas D. Hull III President and Chief Executive Officer Date: September 1, 2023

 
Exhibit 31.2 CERTIFICATION I, Donald T. Gardner III, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Kewaunee Scientific Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. /s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance and Chief Financial Officer Date: September 1, 2023

 
Exhibit 32.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Kewaunee Scientific Corporation (the “Company”) for the period ended July 31, 2023, I, Thomas D. Hull III, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: (1) such Form 10-Q of the Company for the period ended July 31, 2023, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) the information contained in such Form 10-Q of the Company for the period ended July 31, 2023, fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: September 1, 2023 /s/ Thomas D. Hull III Thomas D. Hull III President and Chief Executive Officer

 
Exhibit 32.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Kewaunee Scientific Corporation (the “Company”) for the period ended July 31, 2023, I, Donald T. Gardner III, Vice President, Finance and Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002, that to my knowledge: (1) such Form 10-Q of the Company for the period ended July 31, 2023, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) the information contained in such Form 10-Q of the Company for the period ended July 31, 2023, fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: September 1, 2023 /s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance and Chief Financial Officer

 
v3.23.2
Cover Page - shares
 3 Months Ended
Jul. 31, 2023
Aug. 29, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jul. 31, 2023  
Document Transition Report false  
Entity File Number 0-5286  
Entity Registrant Name KEWAUNEE SCIENTIFIC CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 38-0715562  
Entity Address, Address Line One 2700 West Front Street  
Entity Address, City or Town Statesville,  
Entity Address, State or Province NC  
Entity Address, Postal Zip Code 28677-2927  
City Area Code 704  
Local Phone Number 873-7202  
Title of 12(b) Security Common Stock, $2.50 par value  
Trading Symbol KEQU  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   2,904,094
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0000055529  
Current Fiscal Year End Date --04-30  
v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Income Statement [Abstract]    
Net sales $ 49,839 $ 50,123
Cost of products sold 37,925 43,927
Gross profit 11,914 6,196
Operating expenses 8,106 6,592
Operating profit (loss) 3,808 (396)
Pension expense (41) (27)
Other income, net 75 467
Interest expense (430) (384)
Profit (loss) before income taxes 3,412 (340)
Income tax expense 897 379
Net earnings (loss) 2,515 (719)
Less: Net earnings attributable to the non-controlling interest 41 28
Net earnings (loss) attributable to Kewaunee Scientific Corporation $ 2,474 $ (747)
Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders    
Basic (in dollars per share) $ 0.87 $ (0.27)
Diluted (in dollars per share) $ 0.86 $ (0.27)
Weighted average number of common shares outstanding    
Basic (in shares) 2,860 2,807
Diluted (in shares) 2,885 2,807
v3.23.2
Condensed Consolidated Statements of Comprehensive Earnings (Loss) (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Statement of Comprehensive Income [Abstract]    
Net earnings (loss) $ 2,515 $ (719)
Other comprehensive loss, net of tax:    
Foreign currency translation adjustments (144) (224)
Other comprehensive loss (144) (224)
Comprehensive earnings (loss), net of tax 2,371 (943)
Less: Comprehensive income attributable to the non-controlling interest 41 28
Comprehensive earnings (loss) attributable to Kewaunee Scientific Corporation $ 2,330 $ (971)
v3.23.2
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Retained Earnings
Accumulated Other Comprehensive Loss
Beginning balance at Apr. 30, 2022 $ 35,694 $ 6,983 $ 4,483 $ (53) $ 28,023 $ (3,742)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings (loss) attributable to Kewaunee Scientific Corporation (747)       (747)  
Other comprehensive loss (224)         (224)
Stock-based compensation (37) 97 (134)      
Ending balance at Jul. 31, 2022 34,686 7,080 4,349 (53) 27,276 (3,966)
Beginning balance at Apr. 30, 2023 37,409 7,084 5,059 (53) 28,761 (3,442)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings (loss) attributable to Kewaunee Scientific Corporation 2,474       2,474  
Other comprehensive loss (144)         (144)
Stock-based compensation (309) 185 (494)      
Ending balance at Jul. 31, 2023 $ 39,430 $ 7,269 $ 4,565 $ (53) $ 31,235 $ (3,586)
v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jul. 31, 2023
Apr. 30, 2023
Current Assets:    
Cash and cash equivalents $ 12,699 $ 8,078
Restricted cash 8,869 5,737
Receivables, less allowance; $560; $476, on each respective date 42,461 46,081
Inventories 22,126 21,889
Prepaid expenses and other current assets 7,365 6,135
Total Current Assets 93,520 87,920
Property, plant and equipment, at cost 63,023 61,368
Accumulated depreciation (45,684) (44,966)
Net Property, Plant and Equipment 17,339 16,402
Right of use assets 8,612 9,170
Other assets 5,347 5,406
Total Assets 124,818 118,898
Current Liabilities:    
Short-term borrowings 5,054 3,587
Current portion of financing liability 659 642
Current portion of financing lease liabilities 86 85
Current portion of operating lease liabilities 1,912 1,967
Accounts payable 22,140 23,599
Employee compensation and amounts withheld 4,903 4,304
Deferred revenue 7,067 4,097
Other accrued expenses 2,408 1,772
Total Current Liabilities 44,229 40,053
Long-term portion of financing liability 27,958 28,132
Long-term portion of financing lease liabilities 143 148
Long-term portion of operating lease liabilities 6,645 7,136
Accrued pension and deferred compensation costs 3,861 3,546
Deferred income taxes 989 943
Other non-current liabilities 453 455
Total Liabilities 84,278 80,413
Commitments and Contingencies
Stockholders' Equity:    
Common stock, $2.50 par value, Authorized – 5,000 shares; Issued – 2,907 shares; 2,833 shares; – Outstanding – 2,904 shares; 2,830 shares, on each respective date 7,269 7,084
Additional paid-in-capital 4,565 5,059
Retained earnings 31,235 28,761
Accumulated other comprehensive loss (3,586) (3,442)
Common stock in treasury, at cost, 3 shares, on each respective date (53) (53)
Total Kewaunee Scientific Corporation Stockholders' Equity 39,430 37,409
Non-controlling interest 1,110 1,076
Total Stockholders' Equity 40,540 38,485
Total Liabilities and Stockholders' Equity $ 124,818 $ 118,898
v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
shares in Thousands, $ in Thousands
Jul. 31, 2023
Apr. 30, 2023
Current Assets:    
Allowance for receivables $ 560 $ 476
Stockholders' Equity:    
Common stock, par value (in dollars per share) $ 2.50 $ 2.50
Common stock, shares authorized (in shares) 5,000 5,000
Common stock, shares issued (in shares) 2,907 2,833
Common stock, shares outstanding (in shares) 2,904 2,830
Treasury stock, shares (in shares) 3 3
v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Cash flows from operating activities:    
Net earnings (loss) $ 2,515 $ (719)
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:    
Depreciation 718 725
Bad debt provision 125 23
Stock-based compensation expense 183 172
Deferred income taxes 46 23
Change in assets and liabilities:    
Receivables 3,496 516
Inventories (237) (1,304)
Accounts payable and other accrued expenses (226) (2,117)
Deferred revenue 2,970 10,587
Other, net (1,418) (4,221)
Net cash provided by operating activities 8,172 3,685
Cash flows from investing activities:    
Capital expenditures (1,654) (390)
Net cash used in investing activities (1,654) (390)
Cash flows from financing activities:    
Proceeds from short-term borrowings 40,597 4,431
Repayments on short-term borrowings (39,130) (6,019)
Proceeds from sale-leaseback financing transaction 0 13,456
Payments on sale-leaseback financing transaction (157) (140)
Payments on long-term lease obligations (4) (58)
Net cash provided by financing activities 1,306 11,670
Effect of exchange rate changes on cash, cash equivalents and restricted cash (71) (325)
Increase in cash, cash equivalents and restricted cash 7,753 14,640
Cash, cash equivalents and restricted cash, beginning of period 13,815 6,894
Cash, cash equivalents and restricted cash, end of period $ 21,568 $ 21,534
v3.23.2
Financial Information
 3 Months Ended
Jul. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Financial Information Financial Information
The unaudited interim Condensed Consolidated Financial Statements of Kewaunee Scientific Corporation (the "Company") have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.
These interim Condensed Consolidated Financial Statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the Consolidated Financial Statements and Notes included in the Company's 2023 Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The Condensed Consolidated Balance Sheet as of April 30, 2023 included in this interim period filing has been derived from the audited consolidated financial statements at that date, but does not include all of the information and related notes required by GAAP for complete financial statements.
The preparation of the interim Condensed Consolidated Financial Statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.
v3.23.2
Cash, Cash Equivalents and Restricted Cash
 3 Months Ended
Jul. 31, 2023
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents consist of cash on hand and highly liquid investments with original maturities of three months or less. During the three months ended July 31, 2023 and twelve months ended April 30, 2023, the Company had cash deposits in excess of FDIC insured limits. The Company has not experienced any losses from such deposits. Restricted cash includes bank deposits of subsidiaries used for performance guarantees against customer orders and domestic bank deposits used as collateral for an outstanding letter of credit.
The Company includes restricted cash along with the cash balance for presentation in the Condensed Consolidated Statements of Cash Flows. The reconciliation between the Condensed Consolidated Balance Sheet and the Condensed Consolidated Statement of Cash Flows is as follows:
July 31, 2023April 30, 2023
Cash and cash equivalents$12,699 $8,078 
Restricted cash8,869 5,737 
Total cash, cash equivalents and restricted cash$21,568 $13,815 
v3.23.2
Revenue Recognition
 3 Months Ended
Jul. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue RecognitionThe Company recognizes revenue when control of a good or service promised in a contract (i.e., performance obligation) is transferred to a customer. Control is obtained when a customer has the ability to direct the use of and obtain substantially all of the remaining benefits from that good or service. The majority of the Company's revenues are recognized over time as the customer receives control as the Company performs work under a contract. However, a portion of the Company's revenues are recognized at a point-in-time as control is transferred at a distinct point in time per the terms of a contract.
Disaggregated Revenue
A summary of net sales transferred to customers over time and at a point in time for the periods ended July 31, 2023 and July 31, 2022 is as follows (in thousands):
Three Months Ended
 July 31, 2023July 31, 2022
 DomesticInternationalTotalDomesticInternationalTotal
Over Time$33,904 $14,419 $48,323 $35,353 $12,655 $48,008 
Point in Time1,516 — 1,516 2,115 — 2,115 
Total$35,420 $14,419 $49,839 $37,468 $12,655 $50,123 

Contract Balances
The closing balances of contract assets included $13,621,000 in accounts receivable and $928,000 in other assets at July 31, 2023. The opening balance of contract assets arising from contracts with customers included $13,459,000 in accounts receivable and $1,191,000 in other assets at April 30, 2023. The closing and opening balances of contract liabilities included in deferred revenue arising from contracts with customers were $7,067,000 at July 31, 2023 and $4,097,000 at April 30, 2023. The timing of revenue recognition, billings and cash collections results in accounts receivable, unbilled receivables, and deferred revenue which are disclosed in the Condensed Consolidated Balance Sheets and in the Notes to the Condensed Consolidated Financial Statements. In general, the Company receives payments from customers based on a billing schedule established in its contracts. Unbilled receivables represent amounts earned which have not yet been billed in accordance with contractually stated billing terms and are included in receivables on the Condensed Consolidated Balance Sheets. Receivables are recorded when the right to consideration becomes unconditional and the Company has a right to invoice the customer. Deferred revenue relates to payments received in advance of performance under the contract. Deferred revenue is recognized as revenue as (or when) the Company performs under the contract. Approximately 100% of the contract liability balances at April 30, 2023 and July 31, 2023 are expected to be recognized as revenue during the respective succeeding 12 months.
v3.23.2
Inventories
 3 Months Ended
Jul. 31, 2023
Inventory Disclosure [Abstract]  
Inventories Inventories
The Company measures inventory using the first-in, first-out method at the lower of cost or net realizable value. Inventories consisted of the following (in thousands):
July 31, 2023April 30, 2023
Finished products$3,537 $3,412 
Work in process2,138 2,380 
Raw materials16,451 16,097 
Total$22,126 $21,889 
The Company's International subsidiaries' inventories were $2,902,000 at July 31, 2023 and $2,740,000 at April 30, 2023 and are included in the above tables.
v3.23.2
Fair Value of Financial Instruments
 3 Months Ended
Jul. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
The Company's financial instruments consist primarily of cash and equivalents, mutual funds, short-term borrowings, and the cash surrender value of life insurance policies. The carrying value of these assets and liabilities approximates their fair value. The following tables summarize the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of July 31, 2023 and April 30, 2023 (in thousands):
 July 31, 2023
Financial AssetsLevel 1Level 2Total
Trading securities held in non-qualified compensation plans (1)
$1,324 $— $1,324 
Cash surrender value of life insurance policies (1)
— 1,401 1,401 
Total$1,324 $1,401 $2,725 
Financial Liabilities
Non-qualified compensation plans (2)
$— $3,185 $3,185 
Total$— $3,185 $3,185 
 April 30, 2023
Financial AssetsLevel 1Level 2Total
Trading securities held in non-qualified compensation plans (1)
$1,105 $— $1,105 
Cash surrender value of life insurance policies (1)
— 1,358 1,358 
Total$1,105 $1,358 $2,463 
Financial Liabilities
Non-qualified compensation plans (2)
$— $2,910 $2,910 
Total$— $2,910 $2,910 
(1)The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value.
(2)Plan liabilities are equal to the individual participants' account balances and other earned retirement benefits.
v3.23.2
Long-term Debt and Other Credit Arrangements
 3 Months Ended
Jul. 31, 2023
Debt Disclosure [Abstract]  
Long-term Debt and Other Credit Arrangements Long-term Debt and Other Credit Arrangements
At April 30, 2023, advances of $3.5 million were outstanding under the Company's Revolving Credit Facility. Amounts available under the Revolving Credit Facility were $10.3 million at April 30, 2023. The borrowing rate under the Revolving Credit Facility was 9.02% as of April 30, 2023. The Company's International subsidiaries had a balance outstanding of $39,000 in short-term borrowings related to overdraft protection and short-term loan arrangements. At April 30, 2023, the Company was in compliance with all of the financial covenants under its Revolving Credit Facility.
At July 31, 2023, there were $5.0 million outstanding under the Revolving Credit Facility, with remaining borrowing capacity under the Revolving Credit Facility of $8.3 million. The borrowing rate under the Revolving Credit Facility was 9.33% as of July 31, 2023. In addition, the Company's International subsidiaries have a balance outstanding of $54,000 in short-term borrowings related to overdraft protection and short-term loan arrangements. As of July 31, 2023, the Company was in compliance with all of the financial covenants under its Revolving Credit Facility.
v3.23.2
Sale-Leaseback Financing Transaction
 3 Months Ended
Jul. 31, 2023
Financing Liability [Abstract]  
Sale-Leaseback Financing Transaction Sale-Leaseback Financing Transaction
On December 22, 2021, the Company entered into an Agreement for Purchase and Sale of Real Property with CAI Investments Sub-Series 100 LLC, a Nevada limited liability company (the "Buyer"), for the Company’s headquarters and manufacturing facilities located at 2700 West Front Street in Statesville, North Carolina (the "Sale Agreement").
The Sale Agreement was finalized on March 24, 2022 and coincided with the Company and CAI Investments Medical Products I Master Lessee LLC ("Lessor") entering into a lease agreement. The lease arrangement is for a 20-year term, with four renewal options of five years each. Under the terms of the lease agreement, the Company’s initial basic rent is approximately $158,000 per month, with annual increases of approximately 2% each year of the initial term.
The Company accounted for the Sale-Leaseback Arrangement as a financing transaction as the lease agreement was determined to be a finance lease due to the significance of the present value of the lease payments, using a discount rate of 4.75% to reflect
the Company’s incremental borrowing rate, compared to the fair value of the leased property as of the lease commencement date. In measuring the lease payments for the present value analysis, the Company elected the practical expedient to combine the lease component (the leased facilities) with the non-lease component (property management provided by the Buyer/Lessor) into a single lease component.
The presence of a finance lease indicates that control of the property has not transferred to the Buyer/Lessor and, as such, the transaction was deemed a failed sale-leaseback and accounted for as a financing arrangement. As a result of this determination, the Company is viewed as having received the sale proceeds from the Buyer/Lessor in the form of a hypothetical loan collateralized by its leased facilities. The hypothetical loan is payable as principal and interest in the form of “lease payments” to the Buyer/Lessor. As such, the Company will not derecognize the property from its books for accounting purposes until the lease ends. No gain or loss was recognized under GAAP related to the Sale-Leaseback Arrangement.
As of July 31, 2023, the carrying value of the financing liability was $28,617,000, net of $692,000 in debt issuance costs, of which $659,000 was classified as current on the Consolidated Balance Sheet with $27,958,000 classified as long-term. As of April 30, 2023, the carrying value of the financing liability was $28,774,000, net of $708,000 in debt issuance costs, of which $642,000 was classified as current on the Consolidated Balance Sheet with $28,132,000 classified as long-term. The monthly lease payments are split between a reduction of principal and interest expense using the effective interest rate method. Interest expense associated with the financing arrangement was $325,000 and $332,000 for the three months ended July 31, 2023 and July 31, 2022, respectively.
The Company will depreciate the building down to zero over the 20-year assumed economic life of the Property so that at the end of the lease term, the remaining carrying amount of the financing liability will equal the carrying amount of the land of $41,000.
Remaining future cash payments related to the financing liability as of July 31, 2023 are as follows:
($ in thousands)
Remainder of 2024$1,449 
20251,970 
20262,009 
20272,050 
20282,090 
Thereafter33,867 
Total Minimum Liability Payments43,435 
Imputed Interest(14,818)
Total$28,617 
v3.23.2
Leases
 3 Months Ended
Jul. 31, 2023
Leases [Abstract]  
Leases Leases
The Company recognizes lease assets and lease liabilities reflecting the rights and obligations created by operating type leases for real estate and equipment in both the U.S. and internationally and financing leases for a truck and IT equipment in the U.S. At July 31, 2023 and April 30, 2023, right-of-use assets totaled $8,612,000 and $9,170,000, respectively. Operating cash paid to settle lease liabilities was $639,000 and $524,000 for the three months ended July 31, 2023 and July 31, 2022, respectively. The Company's leases have remaining lease terms of up to 9 years. In addition, some of the leases may include options to extend the leases for up to 5 years or options to terminate the leases within 1 year. Operating lease expenses were $867,000 for the three months ended July 31, 2023, inclusive of period cost for short-term leases, not included in lease liabilities, of $228,000. Operating lease expenses were $835,000 for the three months ended July 31, 2022, inclusive of period cost for short-term leases, not included in lease liabilities, of $311,000.
At July 31, 2023, the weighted average remaining lease term for the capitalized operating leases was 4.9 years and the weighted average discount rate was 5.0%. For the financing leases, the weighted average remaining lease term was 2.9 years and the weighted average discount rate was 6.7%. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of those lease payments. The Company uses the implicit rate when readily determinable.
Future minimum lease payments under non-cancelable leases as of July 31, 2023 were as follows:
OperatingFinancing
Remainder of fiscal 2024$1,730 $83 
20252,172 91 
20261,917 71 
20271,654 — 
20281,127 — 
Thereafter1,377 — 
Total Minimum Lease Payments9,977 245 
Imputed Interest(1,421)(16)
Total$8,556 $229 
Leases Leases
The Company recognizes lease assets and lease liabilities reflecting the rights and obligations created by operating type leases for real estate and equipment in both the U.S. and internationally and financing leases for a truck and IT equipment in the U.S. At July 31, 2023 and April 30, 2023, right-of-use assets totaled $8,612,000 and $9,170,000, respectively. Operating cash paid to settle lease liabilities was $639,000 and $524,000 for the three months ended July 31, 2023 and July 31, 2022, respectively. The Company's leases have remaining lease terms of up to 9 years. In addition, some of the leases may include options to extend the leases for up to 5 years or options to terminate the leases within 1 year. Operating lease expenses were $867,000 for the three months ended July 31, 2023, inclusive of period cost for short-term leases, not included in lease liabilities, of $228,000. Operating lease expenses were $835,000 for the three months ended July 31, 2022, inclusive of period cost for short-term leases, not included in lease liabilities, of $311,000.
At July 31, 2023, the weighted average remaining lease term for the capitalized operating leases was 4.9 years and the weighted average discount rate was 5.0%. For the financing leases, the weighted average remaining lease term was 2.9 years and the weighted average discount rate was 6.7%. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of those lease payments. The Company uses the implicit rate when readily determinable.
Future minimum lease payments under non-cancelable leases as of July 31, 2023 were as follows:
OperatingFinancing
Remainder of fiscal 2024$1,730 $83 
20252,172 91 
20261,917 71 
20271,654 — 
20281,127 — 
Thereafter1,377 — 
Total Minimum Lease Payments9,977 245 
Imputed Interest(1,421)(16)
Total$8,556 $229 
v3.23.2
Earnings Per Share
 3 Months Ended
Jul. 31, 2023
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Basic earnings per share is based on the weighted average number of common shares outstanding during the year. Diluted earnings per share reflects the assumed exercise of outstanding options and the conversion of restricted stock units ("RSUs") under the Company's various stock compensation plans, except when RSUs and options have an antidilutive effect. There were 33,700 and 104,141 antidilutive RSUs and options outstanding at July 31, 2023 and July 31, 2022, respectively. The following is a reconciliation of basic to diluted weighted average common shares outstanding (in thousands):
Three Months Ended
July 31, 2023July 31, 2022
Basic2,860 2,807 
Dilutive effect of stock options and RSUs25 — 
Weighted average common shares outstanding - diluted2,885 2,807 
v3.23.2
Stock Options and Stock-based Compensation
 3 Months Ended
Jul. 31, 2023
Equity [Abstract]  
Stock Options and Stock-based Compensation Stock Options and Stock-based Compensation
The Company recognizes compensation costs related to stock options and other stock awards granted by the Company as operating expenses over their vesting period.
In June 2023, the Company granted 87,220 RSUs under the 2017 Omnibus Incentive Plan ("2017 Plan"). These RSUs include both a service and a performance component, vesting over a three-year period. The recognized expense is based upon the vesting period for service criteria and estimated attainment of the performance criteria at the end of the three-year period, based on the ratio of cumulative days of service to total days over the three-year period. The Company recorded stock-based compensation expense during the three months ended July 31, 2023 of $173,000 with the remaining estimated stock-based compensation expense of $2,032,000 to be recorded over the remaining vesting periods. The Company recorded stock-based compensation expense during the three months ended July 31, 2022 of $131,000. Directors' fees paid with shares of common stock in lieu of cash in accordance with Director compensation guidelines were $10,000 and $41,000 for the three month periods ended July 31, 2023 and July 31, 2022, respectively, and were also included in the stock-based compensation on the Condensed Consolidated Statements of Cash Flows.
v3.23.2
Income Taxes
 3 Months Ended
Jul. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes . Income Taxes
Income tax expense of $897,000 and $379,000 was recorded for the three months ended July 31, 2023 and July 31, 2022, respectively. The effective tax rate was 26.3% and (111.5)% for the three months ended July 31, 2023 and July 31, 2022, respectively. The effective tax rate for the three months ended July 31, 2023 reflects the impact of foreign operations which are taxed at different rates than the U.S. tax rate of 21%, combined with expected current year tax expense for the Company's domestic operations in excess of the change in domestic valuation allowance required for the fiscal year. The effective tax rate for the three months ended July 31, 2022 reflected the impact of foreign operations and the recording of a valuation allowance against the deferred tax asset which resulted in the elimination of any U.S. income tax benefit for pretax losses incurred during the period.
In August 2019, the Company revoked its indefinite reinvestment of foreign unremitted earnings position in compliance with ASC 740 "Income Taxes" and terminated its indefinite reinvestment of unremitted earnings assertion for the Singapore and
Kewaunee Labway India Pvt. Ltd. international subsidiaries. The Company has a deferred tax liability of $1,363,000 and $1,318,000 for the withholding tax related to Kewaunee Labway India Pvt. Ltd. as of July 31, 2023 and April 30, 2023, respectively.
v3.23.2
Defined Benefit Pension Plans
 3 Months Ended
Jul. 31, 2023
Retirement Benefits [Abstract]  
Defined Benefit Pension Plans Defined Benefit Pension Plans
The Company has non-contributory defined benefit pension plans covering substantially all domestic salaried and hourly employees. These plans were amended as of April 30, 2005; no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. There were no Company contributions paid to the plans for the three months ended July 31, 2023 and July 31, 2022. The Company assumed an expected long-term rate of return of 7.75% for the periods ended July 31, 2023 and July 31, 2022.
Pension expense consisted of the following (in thousands):
Three Months Ended
July 31, 2023July 31, 2022
Service cost$— $— 
Interest cost224 322 
Expected return on plan assets(328)(535)
Recognition of net loss145 240 
Net periodic pension expense$41 $27 
v3.23.2
Segment Information
 3 Months Ended
Jul. 31, 2023
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company's operations are classified into two business segments: Domestic and International. The Domestic business segment principally designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, worksurfaces, workstations, workbenches, and computer enclosures. The International business segment, which consists of the Company's foreign subsidiaries, provides products and services, including facility design, detailed engineering, construction, and project management from the planning stage through testing and commissioning of laboratories. Intersegment transactions are recorded at normal profit margins. All intercompany balances and transactions have been eliminated. Certain corporate expenses shown below have not been allocated to the business segments.
The following tables provide financial information by business segment and unallocated corporate expenses for the periods ended July 31, 2023 and 2022 (in thousands):
Domestic
Operations		International
Operations		Corporate /
Eliminations		Total
Three months ended July 31, 2023
Revenues from external customers$35,420 $14,419 $— $49,839 
Intersegment revenues51 661 (712)— 
Earnings (loss) before income taxes3,623 793 (1,004)3,412 
Three months ended July 31, 2022
Revenues from external customers$37,468 $12,655 $— $50,123 
Intersegment revenues796 1,621 (2,417)— 
Earnings (loss) before income taxes98 1,094 (1,532)(340)
v3.23.2
New Accounting Standards
 3 Months Ended
Jul. 31, 2023
Accounting Policies [Abstract]  
New Accounting Standards New Accounting StandardsIn June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments," which replaces the current incurred loss method used for determining credit losses on financial assets, including trade receivables, with an expected credit loss method. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company adopted this standard in fiscal year 2024. The adoption of this standard did not have a significant impact on the Company's consolidated financial position or results of operations.
v3.23.2
New Accounting Standards (Policies)
 3 Months Ended
Jul. 31, 2023
Accounting Policies [Abstract]  
New Accounting Standards In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments," which replaces the current incurred loss method used for determining credit losses on financial assets, including trade receivables, with an expected credit loss method. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company adopted this standard in fiscal year 2024. The adoption of this standard did not have a significant impact on the Company's consolidated financial position or results of operations.
v3.23.2
Cash, Cash Equivalents and Restricted Cash (Tables)
 3 Months Ended
Jul. 31, 2023
Cash and Cash Equivalents [Abstract]  
Schedule of Cash, Cash Equivalents, and Restricted Cash The reconciliation between the Condensed Consolidated Balance Sheet and the Condensed Consolidated Statement of Cash Flows is as follows:
July 31, 2023April 30, 2023
Cash and cash equivalents$12,699 $8,078 
Restricted cash8,869 5,737 
Total cash, cash equivalents and restricted cash$21,568 $13,815 
v3.23.2
Revenue Recognition (Tables)
 3 Months Ended
Jul. 31, 2023
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
A summary of net sales transferred to customers over time and at a point in time for the periods ended July 31, 2023 and July 31, 2022 is as follows (in thousands):
Three Months Ended
 July 31, 2023July 31, 2022
 DomesticInternationalTotalDomesticInternationalTotal
Over Time$33,904 $14,419 $48,323 $35,353 $12,655 $48,008 
Point in Time1,516 — 1,516 2,115 — 2,115 
Total$35,420 $14,419 $49,839 $37,468 $12,655 $50,123 
v3.23.2
Inventories (Tables)
 3 Months Ended
Jul. 31, 2023
Inventory Disclosure [Abstract]  
Summary of Inventories Inventories consisted of the following (in thousands):
July 31, 2023April 30, 2023
Finished products$3,537 $3,412 
Work in process2,138 2,380 
Raw materials16,451 16,097 
Total$22,126 $21,889 
v3.23.2
Fair Value of Financial Instruments (Tables)
 3 Months Ended
Jul. 31, 2023
Fair Value Disclosures [Abstract]  
Summary of Fair Value Hierarchy for Financial Assets and Liabilities Measured Recurring Basis The following tables summarize the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of July 31, 2023 and April 30, 2023 (in thousands):
 July 31, 2023
Financial AssetsLevel 1Level 2Total
Trading securities held in non-qualified compensation plans (1)
$1,324 $— $1,324 
Cash surrender value of life insurance policies (1)
— 1,401 1,401 
Total$1,324 $1,401 $2,725 
Financial Liabilities
Non-qualified compensation plans (2)
$— $3,185 $3,185 
Total$— $3,185 $3,185 
 April 30, 2023
Financial AssetsLevel 1Level 2Total
Trading securities held in non-qualified compensation plans (1)
$1,105 $— $1,105 
Cash surrender value of life insurance policies (1)
— 1,358 1,358 
Total$1,105 $1,358 $2,463 
Financial Liabilities
Non-qualified compensation plans (2)
$— $2,910 $2,910 
Total$— $2,910 $2,910 
(1)The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value.
(2)Plan liabilities are equal to the individual participants' account balances and other earned retirement benefits.
v3.23.2
Sale-Leaseback Financing Transaction (Tables)
 3 Months Ended
Jul. 31, 2023
Financing Liability [Abstract]  
Schedule of Remaining Future Cash Payments for Financing Liability Remaining future cash payments related to the financing liability as of July 31, 2023 are as follows:
($ in thousands)
Remainder of 2024$1,449 
20251,970 
20262,009 
20272,050 
20282,090 
Thereafter33,867 
Total Minimum Liability Payments43,435 
Imputed Interest(14,818)
Total$28,617 
v3.23.2
Leases (Tables)
 3 Months Ended
Jul. 31, 2023
Leases [Abstract]  
Schedule of Operating Lease Maturity
Future minimum lease payments under non-cancelable leases as of July 31, 2023 were as follows:
OperatingFinancing
Remainder of fiscal 2024$1,730 $83 
20252,172 91 
20261,917 71 
20271,654 — 
20281,127 — 
Thereafter1,377 — 
Total Minimum Lease Payments9,977 245 
Imputed Interest(1,421)(16)
Total$8,556 $229 
Schedule of Finance Lease Maturity
Future minimum lease payments under non-cancelable leases as of July 31, 2023 were as follows:
OperatingFinancing
Remainder of fiscal 2024$1,730 $83 
20252,172 91 
20261,917 71 
20271,654 — 
20281,127 — 
Thereafter1,377 — 
Total Minimum Lease Payments9,977 245 
Imputed Interest(1,421)(16)
Total$8,556 $229 
v3.23.2
Earnings Per Share (Tables)
 3 Months Ended
Jul. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted The following is a reconciliation of basic to diluted weighted average common shares outstanding (in thousands):
Three Months Ended
July 31, 2023July 31, 2022
Basic2,860 2,807 
Dilutive effect of stock options and RSUs25 — 
Weighted average common shares outstanding - diluted2,885 2,807 
v3.23.2
Defined Benefit Pension Plans (Tables)
 3 Months Ended
Jul. 31, 2023
Retirement Benefits [Abstract]  
Pension Expenses
Pension expense consisted of the following (in thousands):
Three Months Ended
July 31, 2023July 31, 2022
Service cost$— $— 
Interest cost224 322 
Expected return on plan assets(328)(535)
Recognition of net loss145 240 
Net periodic pension expense$41 $27 
v3.23.2
Segment Information (Tables)
 3 Months Ended
Jul. 31, 2023
Segment Reporting [Abstract]  
Segment Information The following tables provide financial information by business segment and unallocated corporate expenses for the periods ended July 31, 2023 and 2022 (in thousands):
Domestic
Operations		International
Operations		Corporate /
Eliminations		Total
Three months ended July 31, 2023
Revenues from external customers$35,420 $14,419 $— $49,839 
Intersegment revenues51 661 (712)— 
Earnings (loss) before income taxes3,623 793 (1,004)3,412 
Three months ended July 31, 2022
Revenues from external customers$37,468 $12,655 $— $50,123 
Intersegment revenues796 1,621 (2,417)— 
Earnings (loss) before income taxes98 1,094 (1,532)(340)
v3.23.2
Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Jul. 31, 2023
Apr. 30, 2023
Jul. 31, 2022
Apr. 30, 2022
Cash and Cash Equivalents [Abstract]        
Cash and cash equivalents $ 12,699 $ 8,078    
Restricted cash 8,869 5,737    
Total cash, cash equivalents and restricted cash $ 21,568 $ 13,815 $ 21,534 $ 6,894
v3.23.2
Revenue Recognition - Summary of Net Sales Transferred to Customers at a Point in Time and Over Time (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Disaggregation of Revenue [Line Items]    
Net sales transferred to customers $ 49,839 $ 50,123
Over Time    
Disaggregation of Revenue [Line Items]    
Net sales transferred to customers 48,323 48,008
Point in Time    
Disaggregation of Revenue [Line Items]    
Net sales transferred to customers 1,516 2,115
Domestic    
Disaggregation of Revenue [Line Items]    
Net sales transferred to customers 35,420 37,468
Domestic | Over Time    
Disaggregation of Revenue [Line Items]    
Net sales transferred to customers 33,904 35,353
Domestic | Point in Time    
Disaggregation of Revenue [Line Items]    
Net sales transferred to customers 1,516 2,115
International    
Disaggregation of Revenue [Line Items]    
Net sales transferred to customers 14,419 12,655
International | Over Time    
Disaggregation of Revenue [Line Items]    
Net sales transferred to customers 14,419 12,655
International | Point in Time    
Disaggregation of Revenue [Line Items]    
Net sales transferred to customers $ 0 $ 0
v3.23.2
Revenue Recognition - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jul. 31, 2023
Apr. 30, 2023
Disaggregation of Revenue [Line Items]    
Contract liabilities $ 7,067 $ 4,097
Contract liability recognized as revenue percentage 100.00% 100.00%
Accounts receivable    
Disaggregation of Revenue [Line Items]    
Contract assets $ 13,621 $ 13,459
Other assets    
Disaggregation of Revenue [Line Items]    
Contract assets $ 928 $ 1,191
v3.23.2
Inventories - Summary of Inventories (Detail) - USD ($)
$ in Thousands
Jul. 31, 2023
Apr. 30, 2023
Inventory Disclosure [Abstract]    
Finished products $ 3,537 $ 3,412
Work in process 2,138 2,380
Raw materials 16,451 16,097
Total $ 22,126 $ 21,889
v3.23.2
Inventories - Additional Information (Detail) - USD ($)
$ in Thousands
Jul. 31, 2023
Apr. 30, 2023
Inventory [Line Items]    
Inventories $ 22,126 $ 21,889
International Subsidiaries    
Inventory [Line Items]    
Inventories $ 2,902 $ 2,740
v3.23.2
Fair Value of Financial Instruments - Summary of Fair Value Hierarchy for Financial Assets and Liabilities Measured Recurring Basis (Detail)
$ in Thousands
Jul. 31, 2023
USD ($)
CompensationPlan
Apr. 30, 2023
USD ($)
CompensationPlan
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Assets $ 2,725 $ 2,463
Financial Liabilities $ 3,185 $ 2,910
Number of non-qualified compensation plans maintained | CompensationPlan 2 2
Non-qualified compensation plans    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Liabilities $ 3,185 $ 2,910
Trading securities held in non-qualified compensation plans    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Assets 1,324 1,105
Cash surrender value of life insurance policies    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Assets 1,401 1,358
Level 1    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Assets 1,324 1,105
Financial Liabilities 0 0
Level 1 | Non-qualified compensation plans    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Liabilities 0 0
Level 1 | Trading securities held in non-qualified compensation plans    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Assets 1,324 1,105
Level 1 | Cash surrender value of life insurance policies    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Assets 0 0
Level 2    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Assets 1,401 1,358
Financial Liabilities 3,185 2,910
Level 2 | Non-qualified compensation plans    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Liabilities 3,185 2,910
Level 2 | Trading securities held in non-qualified compensation plans    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Assets 0 0
Level 2 | Cash surrender value of life insurance policies    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Financial Assets $ 1,401 $ 1,358
v3.23.2
Long-term Debt and Other Credit Arrangements (Details) - USD ($)
$ in Thousands
Jul. 31, 2023
Apr. 30, 2023
International Subsidiaries    
Debt Instrument [Line Items]    
Short-term borrowings $ 54 $ 39
Revolving Credit Facility | Credit Agreement, Mid Cap Funding IV Trust | Line of Credit    
Debt Instrument [Line Items]    
Outstanding advances under the long-term debt 5,000 3,500
Remaining borrowing capacity $ 8,300 $ 10,300
Interest rate at period end 9.33% 9.02%
v3.23.2
Sale-Leaseback Financing Transaction - Narrative (Details)
$ in Thousands
 3 Months Ended
Jul. 31, 2023
USD ($)
renewalOption
Jul. 31, 2022
USD ($)
Apr. 30, 2023
USD ($)
Financing Liability [Abstract]      
Term of agreement 20 years    
Number of renewal options | renewalOption 4    
Renewal term 5 years    
Initial basic monthly rent $ 158    
Annual rental increase, as a percent 2.00%    
Discount rate 4.75%    
Gain (loss) on sale leaseback agreement $ 0    
Financing liability 28,617   $ 28,774
Debt issuance costs on financing liability 692   708
Current portion of financing liability 659   642
Long-term portion of financing liability 27,958   28,132
Interest expense on financing liability 325 $ 332  
Financing Liability [Line Items]      
Property, plant and equipment, at cost $ 63,023   $ 61,368
Building      
Financing Liability [Line Items]      
Useful Life (in years) 20 years    
Land      
Financing Liability [Line Items]      
Property, plant and equipment, at cost $ 41    
v3.23.2
Sale-Leaseback Financing Transaction - Remaining Future Cash Payments (Details) - USD ($)
$ in Thousands
Jul. 31, 2023
Apr. 30, 2023
Financing Liability [Abstract]    
Remainder of 2024 $ 1,449  
2024 1,970  
2025 2,009  
2026 2,050  
2027 2,090  
Thereafter 33,867  
Total Minimum Liability Payments 43,435  
Imputed Interest (14,818)  
Total $ 28,617 $ 28,774
v3.23.2
Leases - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Apr. 30, 2023
Leases [Abstract]      
Right of use assets $ 8,612   $ 9,170
Operating cash paid to settle lease liabilities $ 639 $ 524  
Remaining lease term (in years) 9 years    
Option to extend, term (in years) 5 years    
Option to terminate, term (in years) 1 year    
Operating lease, expense $ 867 835  
Operating lease, short term, expense $ 228 $ 311  
Weighted average remaining lease term, operating lease (in years) 4 years 10 months 24 days    
Weighted average discount rate, operating lease 5.00%    
Weighted average remaining lease term, finance lease (in years) 2 years 10 months 24 days    
Weighted average discount rate, finance lease 6.70%    
v3.23.2
Leases - Schedule of Operating and Finance Lease Maturity (Details)
$ in Thousands
Jul. 31, 2023
USD ($)
Operating  
Remainder of fiscal 2024 $ 1,730
2025 2,172
2026 1,917
2027 1,654
2028 1,127
Thereafter 1,377
Total Minimum Lease Payments 9,977
Imputed Interest (1,421)
Total 8,556
Financing  
Remainder of fiscal 2024 83
2025 91
2026 71
2027 0
2028 0
Thereafter 0
Total Minimum Lease Payments 245
Imputed Interest (16)
Total $ 229
v3.23.2
Earnings Per Share - Additional Information (Detail) - shares
 3 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Earnings Per Share [Abstract]    
Anti-dilutive options exclude from computation of earning per share (in shares) 33,700 104,141
v3.23.2
Earnings Per Share Schedule of Earnings Per Common Share (Details) - shares
shares in Thousands
 3 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Weighted average number of common shares outstanding    
Basic (in shares) 2,860 2,807
Dilutive effect of stock options and RSUs (in shares) 25 0
Weighted average common shares outstanding - diluted (in shares) 2,885 2,807
v3.23.2
Stock Options and Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Jun. 30, 2023
Jul. 31, 2023
Jul. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Directors' fees paid with shares of common stock in lieu of cash in accordance with Director compensation guidelines   $ 10 $ 41
2017 Plan | Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense   173 $ 131
Remaining estimated compensation expense   $ 2,032  
2017 Plan | Restricted Stock Units (RSUs) | Tranche One      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Restricted stock units granted (in shares) 87,220    
Vesting period (in years) 3 years    
v3.23.2
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Apr. 30, 2023
Income Tax Disclosure [Abstract]      
Income tax expense $ 897 $ 379  
Effective income tax rate 26.30% (111.50%)  
Deferred tax liability, global tax exposure for unremitted earnings of international subsidiaries $ 1,363   $ 1,318
v3.23.2
Defined Benefit Pension Plans - Additional Information (Detail) - USD ($)
 3 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Retirement Benefits [Abstract]    
Employer contributions $ 0 $ 0
Assumed as expected long-term rate of return (as a percent) 7.75% 7.75%
v3.23.2
Defined Benefit Pension Plans - Pension Expenses (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Retirement Benefits [Abstract]    
Service cost $ 0 $ 0
Interest cost 224 322
Expected return on plan assets (328) (535)
Recognition of net loss 145 240
Net periodic pension expense $ 41 $ 27
v3.23.2
Segment Information - Additional Information (Detail)
 3 Months Ended
Jul. 31, 2023
Segment
Segment Reporting [Abstract]  
Number of business segments 2
v3.23.2
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Segment Reporting Information [Line Items]    
Net sales $ 49,839 $ 50,123
Intersegment revenues 0 0
Earnings (loss) before income taxes 3,412 (340)
Corporate / Eliminations    
Segment Reporting Information [Line Items]    
Net sales 0 0
Intersegment revenues (712) (2,417)
Earnings (loss) before income taxes (1,004) (1,532)
Domestic Operations | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 35,420 37,468
Intersegment revenues 51 796
Earnings (loss) before income taxes 3,623 98
International Operations | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 14,419 12,655
Intersegment revenues 661 1,621
Earnings (loss) before income taxes $ 793 $ 1,094
Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Kewaunee Scientific Charts.
Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Kewaunee Scientific Charts.